Clinical success for new allergy tablet from ALK
Denmark’s ALK has announced strong phase II/III results for a drug to treat a type of hay fever that is prevalent in Japan. But the company still has a long way to go before it can capture the market, warns a sector analyst.
BY ANTON GRÆSDAL MAAJEN & STEFAN SINGH KAILAY
Denmark’s ALK announced late last week that its partner for Japan, Torii Pharmaceutical, had reported positive results from its Phase II/III trial into a sublingual allergy immunotherapy tablet (SLIT-tablet) for Japanese cedar tree pollen allergic rhinitis (hay fever).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK heading to FDA with dust mite vaccine
For abonnenter
ALK to close Swiss business unit
For abonnenter
ALK changes organization following executive departure
For abonnenter
